** Shares of Australia's Nanosonics NAN.AX rise as much as
1.4% to A$3
** Morningstar says the healthcare firm's stock is
undervalued; keeps A$4 fair value estimate and narrow moat
rating
** Brokerage also maintains its earnings outlook, saying
recent earnings headwinds will be largely temporary
** Morningstar's FY25 EBIT forecast of A$30 mln ($20.25 mln)
implies strong recovery on FY24 EBIT forecast of A$4 mln
** Avg rating of 11 analysts is equivalent of "hold" and
their median PT is about A$3 –LSEG data
** Stock has lost nearly 33% so far this year, after a 2.5%
gain last year
($1 = 1.4815 Australian dollars)
(Reporting by Rishav Chatterjee in Bengaluru)
((Rishav.Chatterjee@thomsonreuters.com;))